吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25_老虎社区_美港股上老虎

吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25

Minhua笔记2025-12-08

在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel（anitocabtagene autoleucel）在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤（R/R MM）患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。无延迟神经毒性（包括无帕金森样症状、无颅...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2590451393?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-08 11:58","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2590451393","market":"us","top_or_hot":-1,"title":"吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25","media":"Minhua笔记","content":"<div>\n<p>在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel（anitocabtagene autoleucel）在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤（R/R MM）患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。无延迟神经毒性（包括无帕金森样症状、无颅...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-08 11:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b><strong>Minhua笔记</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel（anitocabtagene autoleucel）在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤（R/R MM）患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。无延迟神经毒性（包括无帕金森样症状、无颅...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASH","symbol_name":"Ashland","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","article_id":"2590451393","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","pubTimestamp":1765166299,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ASH":"Ashland","BK4139":"生物科技","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4566":"资本集团","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4578":"CAR-T","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","CRS":"卡朋特科技","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4109":"特种化学制品","PFS":"Provident Financial Services Inc","CR":"crane","BK4568":"美国抗疫概念","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","BK4550":"红杉资本持仓","BK4588":"碎股","GILD":"吉利德科学","ORR":"Militia Long/Short Equity ETF","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4097":"系统软件","BK4187":"航天航空与国防","BK4195":"互助储蓄与抵押信贷金融服务","BK4532":"文艺复兴科技持仓","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","KOL":"Market Vectors-Coal ETF","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"Gilead Anito-cel has low neurotoxicity and high 2-year multiple myeloma survival rate | ASH25","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOL":1,"GILD":0.9,"CR":1,"OS":1,"ORR":1,"CRS":1,"PFS":1,"ASH":1},"content_text":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel（anitocabtagene autoleucel）在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤（R/R MM）患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。无延迟神经毒性（包括无帕金森样症状、无颅神经麻痹、无格林-巴利综合征），CRS发生率83%且均为0/1级，ICANS发生率8%（1例3级，其余2级或以下），所有病例快速解决，无后遗症。12个月PFS率82.1%、18个月67.4%、24个月61.7%；12个月OS率94%、18个月88%、24个月83%，中位PFS和OS未达。Anito-cel在高风险4L+患者中展现可管理安全性和持久疗效，潜在优于Carvykti，支持其作为R/R MM新选择。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。吉利德科学和Arcellx联合研发的靶向BCMA的CAR-T细胞疗法，可能已获得与强生Carvykti（西达基奥仑赛，ciltacabtagene autoleucel）在复发或难治性多发性骨髓瘤（RRMM）领域竞争所需的安全性优势。该疗法预计将于2026年上市。12月6日在美国血液学会 (ASH) 年会上公布的关键性 II 期 iMMagine-1 研究的最新数据显示，在接受 anitocabtagene autoleucel (anito-cel) 治疗的 117 名复发/难治性多发性骨髓瘤 (RRMM) 患者中，未出现任何迟发性神经毒性病例，包括帕金森综合征、颅神经麻痹、格林-巴利综合征或免疫效应细胞相关性肠炎。此前，一些关键意见领袖 (KOL) 表示，anito-cel 的安全性可能比 Carvykti 更具优势，其中一位专家称其未出现迟发性神经毒性“非常出色”。对于 CAR-T 治疗相关的其他副作用，包括细胞因子释放综合征 (CRS) 和免疫效应细胞相关神经毒性综合征 (ICANS)，吉利德报告了更为积极的安全性结果。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。任何级别的 CRS 发生率为 86%，但吉利德指出，83% 的研究参与者要么完全没有 CRS，要么仅出现 1 级 CRS。Anito-cel 在 iMMagine-1 研究中也展现出强劲的疗效，总缓解率 (ORR) 为 96%，其中 74% 的患者达到严格意义上的完全缓解 (sCR) 或完全缓解 (CR)。尽管尚未达到中位无进展生存期 (PFS) 和总生存期 (OS)，但吉利德公布了该 CAR-T 治疗 18 个月和 24 个月的最新数据，这些数据建立在去年 ASH 会议上公布的 6 个月和 12 个月数据的基础上。12 个月、18 个月和 24 个月的 PFS 率分别为 82.1%、67.4% 和 61.7%，OS 率分别为 94%、88% 和 83%。患者对治疗的反应也很快，达到 sCR 或 CR 的中位时间为 3.2 个月。在 96 例可评估微小残留病 (MRD) 检测的患者中，95% 的患者在中位 1 个月内达到 MRD 阴性。吉利德Kite部门执行副总裁Cindy Perettie表示：“iMMagine-1所展现出的深度、持久的疗效，以及可预测、可控的安全性和快速可靠的生产，凸显了anito-cel重新定义治疗的潜力。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}